Allovir, INC Form 4 insider transactions

Director Anthony P. Adamis reports acquisition of stock options in Kalaris Therapeutics following the merger with Kalaris Tx, Inc.

Vikas Sinha, CFO of Allovir, sold 303 shares of common stock on February 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Brett Hagen, Chief Accounting Officer of Allovir, Inc., sold shares of common stock on February 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Edward Miller, General Counsel of Allovir, Inc., sold 106 shares of common stock on February 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Allovir Inc.'s General Counsel, Edward Miller, sold shares to cover tax obligations following the vesting of restricted stock units.

Brett Hagen, Chief Accounting Officer of Allovir, Inc., sold shares of common stock on January 23, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Vikas Sinha, a director, 10% owner, and officer of Allovir, Inc., sold shares to cover tax obligations following a reverse stock split.

AlloVir, Inc. has executed a 1-for-23 reverse stock split of its common stock, effective January 15, 2025, to comply with Nasdaq listing requirements and in connection with the proposed merger with Kalaris Therapeutics, Inc.

Edward Miller, General Counsel of Allovir, Inc., sold 409 shares of common stock on January 10, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Brett Hagen, Chief Accounting Officer of Allovir, Inc., sold 332 shares of common stock on January 10, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Vikas Sinha, a director, 10% owner, and officer of Allovir, Inc., sold shares to cover tax withholding obligations related to vesting restricted stock units.

AlloVir's board of directors has approved a 1-for-23 reverse stock split of its common stock, effective January 15, 2025, in connection with the proposed merger with Kalaris Therapeutics.

AlloVir stockholders have approved a reverse stock split proposal, allowing the board to enact a split between 1-for-15 and 1-for-35 before January 10, 2026.

AlloVir, Inc. has announced the departure of CEO Diana Brainard and the appointment of Vikas Sinha as the new CEO, effective December 19, 2024.

Allovir Inc.'s General Counsel, Edward Miller, transferred 57,549 shares to The Miller Family 2019 Irrevocable Dynasty Trust on December 11, 2024.

AlloVir and Kalaris Therapeutics have agreed to merge, combining their resources to develop Kalaris's lead asset, TH103, a potential best-in-class anti-VEGF therapy for retinal diseases.

Allovir Inc.'s Chief Accounting Officer, Brett R. Hagen, sold 554 shares of common stock to cover tax obligations related to vesting restricted stock units.

A Form 4 filing reveals that Allovir Inc.'s President and CFO, Vikas Sinha, sold shares to cover tax obligations related to vesting restricted stock units.

Allovir Inc.'s General Counsel, Edward Miller, sold 432 shares of common stock to cover tax obligations related to vesting restricted stock units.

Allovir CEO Diana Brainard sold 8,706 shares of common stock at an average price of $0.5485 to cover tax obligations related to the vesting of restricted stock units.

AlloVir and Kalaris Therapeutics have announced a definitive merger agreement, with AlloVir acquiring Kalaris in a stock-for-stock transaction aimed at creating a combined entity focused on advancing novel therapies.

AlloVir and Kalaris Therapeutics have entered into a merger agreement, with Kalaris becoming a wholly-owned subsidiary of AlloVir upon completion.

AlloVir, Inc. and Kalaris Therapeutics, Inc. have announced a definitive merger agreement, with AlloVir acquiring Kalaris in a stock-for-stock transaction aimed at creating a combined company focused on advancing novel therapies.

AlloVir and Kalaris Therapeutics have entered into a definitive merger agreement to focus on developing Kalaris' lead asset, TH103, a novel anti-VEGF therapy for retinal diseases.

AlloVir and Kalaris Therapeutics have agreed to merge, with the combined company focusing on developing treatments for retinal diseases and expected to operate under the name Kalaris Therapeutics, Inc.

AlloVir and Kalaris Therapeutics have agreed to merge in an all-stock transaction, creating a company focused on developing treatments for retinal diseases, with Kalaris' TH103 as the lead asset.

Allovir's CEO, Diana Brainard, sold shares of common stock on November 5, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Edward Miller, General Counsel of Allovir, Inc., sold shares to cover tax withholding obligations related to vesting restricted stock units.

Chief Accounting Officer Hagen Brett R. of Allovir, Inc. reports the sale of 1,655 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Vikas Sinha, CFO of Allovir, sold shares to cover tax withholding obligations related to vesting restricted stock units.